SciELO - Scientific Electronic Library Online

vol.115 issue4Algorithms imaging tests comparison following the first febrile urinary tract infection in childrenPediatric dermatopathology: an overview author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Archivos argentinos de pediatría

Print version ISSN 0325-0075On-line version ISSN 1668-3501


ROSANOVA, María T et al. Ánidulafungin in children: Experience in a tertiary care children's hospital in Argentina. Arch. argent. pediatr. [online]. 2017, vol.115, n.4, pp.374-376. ISSN 0325-0075.

The experience using anidulafungin for the treatment of invasive fungal infections in pediatrics is limited. In this article, we describe our experience in 55 children. Anidulafungin was administered intravenously at a loading dose of 3 mg/kg once daily, followed by 1.5 mg/kg every 24 hours over a mean period of 14 days (range: 7-22 days). Patients' median age was 114 months old (interquartile range: 32-168 months old). All patients had underlying diseases. Among patients with bone marrow transplant, the difference in white blood cell count, transaminase levels, and renal function at baseline and at the end of anidulafungin administration was not significant. No adverse events were reported and no patient died from an anidulafungin-related cause. Anidulafungin may be considered an alternative for the prophylaxis or treatment of invasive fungal infections in pediatrics but methodologically robust studies are needed to confirm this.

Keywords : Anidulafungin; Children; Invasive fungal infections.

        · abstract in Spanish     · text in Spanish     · English ( pdf ) | Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License